Intellia Therapeutics NTLA reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Intellia Therapeutics missed estimated earnings by 16.41%, reporting an EPS of $-1.49 versus an estimate of $-1.28.
Revenue was up $6.06 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.02 which was followed by a 3.22% drop in the share price the next day.
Here's a look at Intellia Therapeutics's past performance:
Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
---|---|---|---|---|
EPS Estimate | -1.31 | -1.10 | -0.94 | -0.84 |
EPS Actual | -1.33 | -1.96 | -1.09 | -0.97 |
Revenue Estimate | 9.42M | 8.54M | 8.26M | 8.66M |
Revenue Actual | 14.03M | 11.25M | 12.85M | 7.20M |
To track all earnings releases for Intellia Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.